Merck submits Keytruda for first-line lung cancer approval in USA

4 May 2018

After a positive first quarter results statement earlier this week showed revenues swelled in large part by Keytruda (pembrolizumab), Merck & Co (NYSE: MRK) announced on Thursday another in a growing list of filings for the ground-breaking checkpoint inhibitor.

The New Jersey, USA-based firm says it has submitted a supplemental Biologics License Application (sBLA) to the US Food and Drug Administration (FDA) to include treatment in the first-line setting for metastatic squamous non-small cell lung cancer (sNSCLC).

The application is supported by more good data from the Phase III KEYNOTE-407 trial investigating the drug in combination with chemotherapy.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK